Studiobio Competitors

At Illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. Illumina’s innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.

Since 1987, Eurofins has grown from one laboratory in Nantes, France to over 65,000 staff across a network of independent companies in 59 countries, operating over 950 laboratories. Performing over 450 million tests every year, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of biological substances and products, as well as providing innovative clinical diagnostic testing services, as one of the leading global emerging players in specialised clinical diagnostics testing. Ever since its IPO on the French stock exchange in 1997, Eurofins has been one of the fastest growing listed European companies.

Making improvements in life possible is more than our vision. It is the reason QIAGEN exists. From combating cancer and diagnosing infectious diseases to keeping food and communities safe, the world's most urgent challenges begin with unlocking the insights hidden in DNA and RNA, the building blocks of life. That is where we come in. We are QIAGEN, a Netherlands-based global leader in Sample to Insight solutions. Our technologies isolate and process DNA, RNA and proteins, prepare them for analysis, and turn complex molecular data into clear, actionable insights. Automation brings it together into seamless workflows for the Life Sciences (academia, pharmaceutical R&D and industrial applications such as forensics) and Molecular Diagnostics for clinical healthcare. Every day, more than 500,000 customers around the world rely on us to extract meaning from genetic material quickly, confidently and accurately, from young scientists and pharma R&D teams to clinical labs and more than 35 Nobel Prize winners. Behind it all are the QIAGENers, more than 5,000 colleagues across 75 nationalities and subsidiaries in 25 countries, united by the three promises in our name: Quality, Ingenuity and Accessibility. We are a partner in progress, backed by a deep commitment to science and better healthcare. That commitment extends beyond the lab to how we operate, including our goal of reaching net zero by 2050. NYSE: QGEN | Frankfurt Prime Standard: QIA Learn more at www.qiagen.com